Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model

Corbett, Holly J., Fernando, Germain J. P., Chen, Xianfeng, Frazer, Ian H. and Kendall, Mark A. F. (2010) Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS One, 5 10: e13460.1-e13460.9. doi:10.1371/journal.pone.0013460

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ219907.pdf Full text (Open Access) application/pdf 3.72MB 199

Author Corbett, Holly J.
Fernando, Germain J. P.
Chen, Xianfeng
Frazer, Ian H.
Kendall, Mark A. F.
Title Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model
Journal name PLoS One   Check publisher's open access policy
ISSN 1932-6203
Publication date 2010-10-18
Sub-type Article (original research)
DOI 10.1371/journal.pone.0013460
Open Access Status DOI
Volume 5
Issue 10
Start page e13460.1
End page e13460.9
Total pages 9
Editor Peter Binfield
Place of publication San Francisco, CA, United States
Publisher Public Library of Science
Collection year 2011
Language eng
Formatted abstract
Background: Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin patch (Nanopatch™) as an alternate delivery system to intramuscular injection for delivering an alum adjuvanted human papillomavirus (HPV) vaccine (Gardasil®) commonly used as a prophylactic vaccine against cervical cancer.

Methodology/Principal Findings: Micro-projection arrays dry-coated with vaccine material (Gardasil®) delivered to C57BL/6 mouse ear skin released vaccine within 5 minutes. To assess vaccine immunogenicity, doses of corresponding to HPV-16 component of the vaccine between 0.43±0.084 ng and 300±120 ng (mean ± SD) were administered to mice at day 0 and day 14. A dose of 55±6.0 ng delivered intracutaneously by micro-projection array was sufficient to produce a maximal virus neutralizing serum antibody response at day 28 post vaccination. Neutralizing antibody titres were sustained out to 16 weeks post vaccination, and, for comparable doses of vaccine, somewhat higher titres were observed with intracutaneous patch delivery than with intramuscular delivery with the needle and syringe at this time point.

Conclusions/Significance: Use of dry micro-projection arrays (Nanopatch™) has the potential to overcome the need for a vaccine cold chain for common vaccines currently delivered by needle and syringe, and to reduce risk of needle-stick injury and vaccine avoidance due to the fear of the needle especially among children.

Keyword Virus-like particles
Epidermal powder immunization
Dendritic cells
Unsafe injections
Immune-responses
Type-16 L1
Infection
Vaccines
Immunogenicity
Cervarix(TM)
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 40 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 50 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 07 Nov 2010, 00:03:20 EST